About AIRDOC-B Company

Taketomi Airdoc was founded in September 2015 and is headquartered in Beijing. By the end of January 2020, the company had established subsidiaries and R&D centers in Beijing, Shanghai, Guangzhou and Hong Kong. Takatomi Airdoc is a global leader and pioneer in the field of artificial intelligence for retinal imaging. The company's early detection, auxiliary diagnosis, and health risk assessment solutions based on artificial intelligence recognition of retinal images have improved traditional early detection and diagnosis methods for chronic diseases through retinal images, multi-modal data analysis, and artificial intelligence deep learning algorithms, to achieve non-invasive, accurate, fast, cost-effective, and large-scale diagnosis of chronic diseases and related health risk assessments in medical institutions and large health scenarios. In August 2020, Eagle Hitomi Airdoc's diabetic retinopathy fundus image auxiliary diagnostic software was approved and marketed by the State Drug Administration. It was the first of its kind to obtain a Class III medical device certificate from the State Drug Administration, and as a result, it began to be used in domestic hospitals to assist and reduce medical diagnosis work for doctors. In order to solve unmet medical and health needs, the company has developed a rich product pipeline related to artificial intelligence retinal imaging, which has been widely used in community clinics, physical examination centers, insurance companies, optometry centers, pharmacies, etc., to provide users with disease assisted diagnosis and health risk assessment.